Sep 8, 2026 06:09AM
Jul 31, 2026 04:31PM
Jun 24, 2026 08:30AM
Jun 12, 2026 05:49AM
Jun 11, 2026 03:18AM
Mar 13, 2026 01:37PM
Feb 18, 2026 06:19AM Novartis reports positive results for remibrutinib in chronic urticaria
Jan 16, 2026 12:01PM
Nov 20, 2025 08:30AM
Nov 17, 2025 08:30AM
Nov 10, 2025 09:31AM
Oct 27, 2025 06:33AM
Sep 30, 2025 05:23PM
Sep 30, 2025 05:23PM Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Sep 30, 2025 04:16PM
Aug 11, 2025 01:20AM
Jul 31, 2025 04:30PM
Jul 31, 2025 04:30PM
Jun 11, 2025 08:30AM
Apr 9, 2025 05:00AM
Mar 27, 2025 08:30AM Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
Mar 20, 2025 07:40PM
Mar 20, 2025 07:37PM
Feb 18, 2025 09:00AM
Jan 16, 2025 04:07PM
Dec 11, 2024 09:44AM
Dec 2, 2024 04:14PM
Nov 5, 2024 07:05AM PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
Oct 28, 2024 04:44PM
Oct 26, 2024 07:50PM
Sep 24, 2024 08:45AM
Sep 20, 2024 09:00AM
Sep 17, 2024 01:00PM
Aug 28, 2024 07:09AM
Aug 7, 2024 02:23PM FDA Approved Novartis' (NVS) fabhalta for Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
Aug 6, 2024 09:00AM
Jul 30, 2024 07:00AM
May 25, 2024 06:00AM
May 7, 2024 07:00AM
Apr 30, 2024 10:14AM
Apr 23, 2024 01:58PM
Apr 17, 2024 01:20AM Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
Apr 15, 2024 02:02PM
Feb 27, 2024 08:05AM
Feb 27, 2024 08:00AM
Feb 25, 2024 02:00PM
Feb 16, 2024 11:20AM
Feb 14, 2024 08:01AM
Feb 14, 2024 08:00AM Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Feb 5, 2024 05:17PM

330,350 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All